Vimarsana
Biggest News Aggregation in the World

Medicines Australia Code News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Medicines Australia Code. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Medicines Australia Code Today - Breaking & Trending Today

Ozempic maker Novo Nordisk wants copycat products banned in Australia - Vimarsana News

Ozempic maker Novo Nordisk wants copycat products banned in Australia

The $600 billion drugmaker Novo Nordisk has become one of Europe’s largest companies off the success of its weight loss drug.

Source: afr.com
Ozempic manufacturer Novo Nordisk's sponsored content to be probed by TGA - Vimarsana News

Ozempic manufacturer Novo Nordisk's sponsored content to be probed by TGA

An obesity “awareness campaign” by the pharmaceutical company behind the world’s top weight loss drug will be reviewed by the Australian regulator for a possible violation of strict prescription medicine advertising laws.

Ozempic manufacturer Novo Nordisk's sponsored content to be probed by TGA - Vimarsana News

Ozempic manufacturer Novo Nordisk's sponsored content to be probed by TGA

An obesity “awareness campaign” by the pharmaceutical company behind the world’s top weight loss drug will be reviewed by the Australian regulator for a possible violation of strict prescription medicine advertising laws.

Source: smh.com.au
Ozempic in Australia: Eucalyptus facing TGA inquiry over email promotion - Vimarsana News

Ozempic in Australia: Eucalyptus facing TGA inquiry over email promotion

Advertising prescription medicines is illegal in Australia. The regulator is probing whether a start-up spruiking a weight-loss drug via email falls foul of the law.

Ozempic in Australia: Eucalyptus facing TGA inquiry over email promotion - Vimarsana News

Ozempic in Australia: Eucalyptus facing TGA inquiry over email promotion

Advertising prescription medicines is illegal in Australia. The regulator is probing whether a start-up spruiking a weight-loss drug via email falls foul of the law.